Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis.

ABSTRACT:

Objective

To assess the possible effect of therapy, disease subtype and severity on H1N1 immunogenicity in patients with SSc.

Methods

Ninety-two patients and 92 age- and gender-matched healthy controls received adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine. Blood samples were collected immediately before and 3 weeks after vaccination to evaluate antibody responses to the H1N1 virus. Efficacy was assessed by seroprotection (SP) and seroconversion (SC) rates and the factor increase in geometric mean antibody titre. Participants received a 21-day symptom diary card and were instructed to report local and systemic adverse events.

Results

SSc patients were predominantly females (91%) and 61% had limited SSc, 12% had severe skin involvement and 57.6% were on i

SUBMITTER: Sampaio-Barros PD 

PROVIDER: S-EPMC7313820 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature